|Mr. Scott P. Carmer||Pres, CEO & Director||518.36k||N/A||1965|
|Mr. John Trainer M.B.A.||Chief Financial Officer||342.44k||N/A||1974|
|Ms. Kristi Jones||Chief Operating Officer||397.48k||N/A||1963|
|Dr. Jeffrey S. Weber||Chief Scientific Advisor & Chairman of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Chad Rubin||Sr. VP of Corp. Affairs||N/A||N/A||N/A|
|Dr. Mathias Oelke||Sr. VP of Preclinical Immunotherapy & Head of Cell Biology||N/A||N/A||N/A|
|Dr. Daniel P. Bednarik||Sr. VP of Molecular Engineering & Protein Design||N/A||N/A||N/A|
|Dr. Jerome Bernard Zeldis||Exec. VP of R&D||N/A||N/A||1950|
|Dr. Robert Douglas Knight M.D.||Chief Medical Officer||N/A||N/A||1951|
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, which is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
NexImmune, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.